Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
战胜癌症仍然是一项极具挑战的任务，药品公司无法夜盘即成。
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt, Germany-based company that is not related to the U.S-based Merck & Co (NYSE:MRK).
默克制药公司周二表示，其抗癌药物Xevinapant的3期临床试验将取消，令德国达姆施塔特的默克集团的研究能力受到威胁。与位于美国的默克及公司（纽交所代码:MRK）无任何关联。
Merck & Co continues its quest to end cancer.
默克及公司继续努力终结癌症。
Meanwhile, Merck & Co just reported first-time positive data for its antibody-drug conjugate therapy aimed at lung and breast cancer patients from its open-label Phase II trial.
同时，默克及公司刚刚公布了第二期开放标签试验，针对肺癌和乳腺癌患者的抗体药物联结疗法的首次阳性数据。
At the beginning of June, Merck also released more good news from its...
6月初，默克还发布了一项利...
登录免费看全文
登录/注册